Loading company…
Vandria develops small-molecule mitophagy inducers for age-related and chronic diseases.
Vandria develops small molecules intended to treat age-related and chronic diseases, with programs focused on muscle tissue and the central nervous system. Its target conditions include mild cognitive impairment, ALS, Parkinson's disease, sporadic body myositis, and sarcopenia. The company is based in Epalinges, Switzerland, and was co-founded by Johan Auwerx and Patrick Aebischer. In August 2024, it raised CHF 10.3 million from Hevolution Foundation and Dolby Family Ventures as part of a larger CHF 28.3 million Series A.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in